Enhancing Drug Safety: Challenges, Solutions, and Recommendations in Post-Marketing Pharmacovigilance

Abstract

Effective post-marketing pharmacovigilance (PV) is necessary to find and lessen these dangers through careful checking, telling about problems, and following rules. Improvements in data study tools, real-world proof, and teamwork ways give fresh chances to make PV work better. This paper examines the challenges of post-marketing PV, explores solutions through advanced tools and regulatory frameworks, and evaluates best practices for optimizing drug safety. We discuss the importance of spontaneous adverse event reporting, the role of real-world evidence in detecting safety signals, and the methodologies used to ensure compliance and efficacy in PV efforts. We propose a strategic approach emphasizing emerging trends, advanced surveillance tools, and collaborative frameworks to address existing gaps and ensure safer drug use in real-world settings.